IL6 and Impaired glucose tolerance: Thus, in a study conducted by Zhang Y. et al., with a 2-week administration of ALA at a daily dose of 600 mg to 13 patients with obesity and impaired glucose tolerance, a significant decrease in IL-6 concentration of 16.7% and TNF-α of 24.6% was obtained [14].